# A PHARMACOGENETIC STUDY OF ALDEHYDE OXIDASE I IN PATIENTS TREATED WITH XK469

## Metadata
**Authors:** Jacqueline Ramírez, Tae Won Kim, Wanqing Liu, Jamie L Myers, Snezana Mirkov, Kouros Owzar, Dorothy Watson, Flora Mulkey, Eric R Gamazon, Wendy Stock, Samir Undevia, Federico Innocenti, Mark J Ratain
**Journal:** Pharmacogenetics and genomics
**Date:** 2014 Feb
**DOI:** [10.1097/FPC.0000000000000023](https://doi.org/10.1097/FPC.0000000000000023)
**PMID:** 24300566
**PMCID:** PMC3901533
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901533/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC3901533/pdf/nihms-542725.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC3901533/pdf/nihms-542725.pdf)

## Abstract

XK469 (NSC 697887) is a selective topoisomerase II β inhibitor eliminated mainly via aldehyde oxidase I (AOX1). We performed a candidate gene study to investigate whether AOX1 genetic variation contributes to interindividual variability in XK469 clearance. Forty-one AOX1 single nucleotide polymorphisms (SNPs) and seven liver expression quantitative trait loci were genotyped in Caucasian patients with advanced refractory solid tumors (n=59) and leukemia (n=33). We found a significant decrease in clearance (τ = −0.32, P = 0.003) in solid tumor patients with rs10931910, although it failed to replicate in the leukemia cohort (τ = 0.18, P = 0.20). Four other AOX1 SNPs were associated with clearance (P = 0.01-0.02) in only one of the two cohorts. Our study provides a starting point for future investigations on the functionality of AOX1 SNPs. However, variability in XK469 clearance cannot be attributed to polymorphisms in AOX1.

Keywords: XK469, aldehyde oxidase I, clearance, phase I

## Supplementary Material

## Acknowledgements

We want to thank Kai Xia from the University of North Carolina at Chapel Hill for his help in data analysis related to the eQTLs.

**Source of funding:** This work was funded in part by U01 GM061393, U01 CA69852 and P30 CA14599.

## Footnotes

## Associated Data

*This section collects any data citations, data availability statements, or supplementary materials included in this article.*

### Supplementary Materials

### Supplementary Materials

## References

1. Undevia SD, Innocenti F, Ramirez J, House L, Desai AA, Skoog LA, Singh DA, et al. A phase I and pharmacokinetic study of the quinoxaline antitumour agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008;44:1684–1692. doi: 10.1016/j.ejca.2008.05.018.  [DOI](https://doi.org/10.1016/j.ejca.2008.05.018) | [PMC free article](/articles/PMC2731567/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18650079/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer&title=A%20phase%20I%20and%20pharmacokinetic%20study%20of%20the%20quinoxaline%20antitumour%20agent%20R(+)XK469%20in%20patients%20with%20advanced%20solid%20tumours.&author=SD%20Undevia&author=F%20Innocenti&author=J%20Ramirez&author=L%20House&author=AA%20Desai&volume=44&publication_year=2008&pages=1684-1692&pmid=18650079&doi=10.1016/j.ejca.2008.05.018&)

2. Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, et al. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008;26:331–338. doi: 10.1007/s10637-008-9129-0.  [DOI](https://doi.org/10.1007/s10637-008-9129-0) | [PMC free article](/articles/PMC4905709/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18425419/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Invest%20New%20Drugs&title=A%20phase%20I%20and%20pharmacokinetic%20study%20of%20XK469R%20(NSC%20698215),%20a%20quinoxaline%20phenoxypropionic%20acid%20derivative,%20in%20patients%20with%20refractory%20acute%20leukemia.&author=W%20Stock&author=SD%20Undevia&author=C%20Bivins&author=F%20Ravandi&author=O%20Odenike&volume=26&publication_year=2008&pages=331-338&pmid=18425419&doi=10.1007/s10637-008-9129-0&)

3. Hartmann T, Terao M, Garattini E, Teutloff C, Alfaro JF, Jones JP, et al. The impact of single nucleotide polymorphisms on human aldehyde oxidase. Drug Metab Dispos. 2012;40:856–864. doi: 10.1124/dmd.111.043828.  [DOI](https://doi.org/10.1124/dmd.111.043828) | [PMC free article](/articles/PMC4738704/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22279051/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Drug%20Metab%20Dispos&title=The%20impact%20of%20single%20nucleotide%20polymorphisms%20on%20human%20aldehyde%20oxidase.&author=T%20Hartmann&author=M%20Terao&author=E%20Garattini&author=C%20Teutloff&author=JF%20Alfaro&volume=40&publication_year=2012&pages=856-864&pmid=22279051&doi=10.1124/dmd.111.043828&)

4. Innocenti F, Cooper GM, Stanaway IB, Gamazon ER, Smith JD, Mirkov S, et al. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet. 2011;7:e1002078. doi: 10.1371/journal.pgen.1002078.  [DOI](https://doi.org/10.1371/journal.pgen.1002078) | [PMC free article](/articles/PMC3102751/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21637794/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=PLoS%20Genet&title=Identification,%20replication,%20and%20functional%20fine-mapping%20of%20expression%20quantitative%20trait%20loci%20in%20primary%20human%20liver%20tissue.&author=F%20Innocenti&author=GM%20Cooper&author=IB%20Stanaway&author=ER%20Gamazon&author=JD%20Smith&volume=7&publication_year=2011&pages=e1002078&pmid=21637794&doi=10.1371/journal.pgen.1002078&)

5. Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 2007;3:1724–1735. doi: 10.1371/journal.pgen.0030161.  [DOI](https://doi.org/10.1371/journal.pgen.0030161) | [PMC free article](/articles/PMC1994707/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17907809/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=PLoS%20Genet&title=Capturing%20heterogeneity%20in%20gene%20expression%20studies%20by%20surrogate%20variable%20analysis.&author=JT%20Leek&author=JD%20Storey&volume=3&publication_year=2007&pages=1724-1735&pmid=17907809&doi=10.1371/journal.pgen.0030161&)

6. Smith MA, Marinaki AM, Arenas M, Shobowale-Bakre M, Lewis CM, Ansari A, et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Drug Metab Dispos. 2012;40:856–864. doi: 10.1111/j.1365-2036.2009.04057.x.  [DOI](https://doi.org/10.1111/j.1365-2036.2009.04057.x) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/19500084/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Drug%20Metab%20Dispos&title=Novel%20pharmacogenetic%20markers%20for%20treatment%20outcome%20in%20azathioprine-treated%20inflammatory%20bowel%20disease.&author=MA%20Smith&author=AM%20Marinaki&author=M%20Arenas&author=M%20Shobowale-Bakre&author=CM%20Lewis&volume=40&publication_year=2012&pages=856-864&pmid=19500084&doi=10.1111/j.1365-2036.2009.04057.x&)

7. Kurzawski M, Dziewanowski K, Safranow K, Drozdzik M. Polymorphism of genes involved in purine metabolism (XDH, AOX1, MOCOS) in kidney transplant recipients receiving azathioprine. Ther Drug Monit. 2012;34:266–274. doi: 10.1097/FTD.0b013e31824aa681.  [DOI](https://doi.org/10.1097/FTD.0b013e31824aa681) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22495427/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ther%20Drug%20Monit&title=Polymorphism%20of%20genes%20involved%20in%20purine%20metabolism%20(XDH,%20AOX1,%20MOCOS)%20in%20kidney%20transplant%20recipients%20receiving%20azathioprine.&author=M%20Kurzawski&author=K%20Dziewanowski&author=K%20Safranow&author=M%20Drozdzik&volume=34&publication_year=2012&pages=266-274&pmid=22495427&doi=10.1097/FTD.0b013e31824aa681&)

8. Steinberg KK, Relling MV, Gallagher ML, Greene CN, Rubin CS, French D, et al. Genetic studies of a cluster of acute lymphoblastic leukemia cases in Churchill County, Nevada. Environ Health Perspect. 2007;115:158–164. doi: 10.1289/ehp.9025.  [DOI](https://doi.org/10.1289/ehp.9025) | [PMC free article](/articles/PMC1817665/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17366837/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Environ%20Health%20Perspect&title=Genetic%20studies%20of%20a%20cluster%20of%20acute%20lymphoblastic%20leukemia%20cases%20in%20Churchill%20County,%20Nevada.&author=KK%20Steinberg&author=MV%20Relling&author=ML%20Gallagher&author=CN%20Greene&author=CS%20Rubin&volume=115&publication_year=2007&pages=158-164&pmid=17366837&doi=10.1289/ehp.9025&)

9. Neumeier M, Weigert J, Schäffler A, Weiss TS, Schmidl C, Büttner R, et al. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochem Biophys Res Commun. 2006;350:731–735. doi: 10.1016/j.bbrc.2006.09.101.  [DOI](https://doi.org/10.1016/j.bbrc.2006.09.101) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17022944/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Biochem%20Biophys%20Res%20Commun&title=Aldehyde%20oxidase%201%20is%20highly%20abundant%20in%20hepatic%20steatosis%20and%20is%20downregulated%20by%20adiponectin%20and%20fenofibric%20acid%20in%20hepatocytes%20in%20vitro.&author=M%20Neumeier&author=J%20Weigert&author=A%20Sch%C3%A4ffler&author=TS%20Weiss&author=C%20Schmidl&volume=350&publication_year=2006&pages=731-735&pmid=17022944&doi=10.1016/j.bbrc.2006.09.101&)

10. Kim JW, Kim ST, Turner AR, Young T, Smith S, Liu W, et al. Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One. 2012;7:e48455. doi: 10.1371/journal.pone.0048455.  [DOI](https://doi.org/10.1371/journal.pone.0048455) | [PMC free article](/articles/PMC3485209/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23119026/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=PLoS%20One&title=Identification%20of%20new%20differentially%20methylated%20genes%20that%20have%20potential%20functional%20consequences%20in%20prostate%20cancer.&author=JW%20Kim&author=ST%20Kim&author=AR%20Turner&author=T%20Young&author=S%20Smith&volume=7&publication_year=2012&pages=e48455&pmid=23119026&doi=10.1371/journal.pone.0048455&)

11. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, Tran TD. Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem. 2010;53:8441–8460. doi: 10.1021/jm100888d.  [DOI](https://doi.org/10.1021/jm100888d) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/20853847/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Med%20Chem&title=Aldehyde%20oxidase:%20an%20enzyme%20of%20emerging%20importance%20in%20drug%20discovery.&author=DC%20Pryde&author=D%20Dalvie&author=Q%20Hu&author=P%20Jones&author=RS%20Obach&volume=53&publication_year=2010&pages=8441-8460&pmid=20853847&doi=10.1021/jm100888d&)
